[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beni-Suef University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":585},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,80,0,25,[9,42,69,88,110,131,154,174,194,221,241,264,284,311,341,363,383,407,430,449,468,492,515,534,556],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100652387","palmitoylethanolamide-modulates-central-sensitisation-and-neuroinflammation-in-chronic-low-back-pain-100652387",false,"NCT07772141","Palmitoylethanolamide Modulates Central Sensitisation and Neuroinflammation in Chronic Low Back Pain","Palmitoylethanolamide Modulates Central Sensitisation and Neuroinflammation in Chronic Low Back Pain: A Randomized Controlled Trial With Neurophysiological and Biomarker Correlates","Inclusion Criteria:\n\n* With chronic pain (more than 3 months)\n* Patients with NRS (4 -7)\n* MRI evidence of disc protrusion or prolapse limited to one or two lumbar discs, without extensive multi-level pathology\n* Diagnosed clinically with low back pain due to disc disease.\n* ASA I and ASA II\n\nExclusion Criteria:\n\n* Neurological disorders\n* psychiatric illness\n* pregnancy\n* prior spinal surgery\n* concurrent use of immunomodulatory drugs\n* contraindications to TMS.\n* Allergy to the drug","ALL","18 Years","65 Years",{"count":21,"type":22},106,"ESTIMATED","INTERVENTIONAL",[25],"NA","Low back pain (LBP) is a public and occupational health problem that is a major professional, economic and social burden. Up to 84% of the general population will experience an episode of LBP during its life time, and recurrence rates are high. Acute LBP is the second reason for consultations in general medicine, and chronic LBP is the eighth. One in five LBP episodes result in sick leave. LBP represents 30% of sick leaves that are longer than 6 months, and 20% of work accidents. LBP has become the leading cause of exclusion from work before the age of 45, and the third cause of work disabilities in France.\n\nIn 2020 globally, LBP affected approximately 619 million people, making it the leading cause of disability worldwide. This number is projected to rise to 843 million by 2050, driven by population growth and aging.",[28],"Chronic Low-back Pain","RECRUITING","2026-08-17",{"date":32,"type":33},"2026-08-19","ACTUAL",{"date":35,"type":33},"2026-01-01",{"date":37,"type":22},"2027-06-10",{"name":39,"class":40},"Beni-Suef University","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100651575","mechanism-based-cervical-rehabilitation-for-chronic-migraine-100651575","NCT07762690","Mechanism-Based Cervical Rehabilitation for Chronic Migraine","Effect of Mechanism-Based Cervical Sensorimotor Rehabilitation on Cervical Muscle Activation, Joint Position Error, and Migraine Burden in Patients With Chronic Migraine: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Male or female adults aged 18-55 years. Diagnosed with chronic migraine according to the International Classification of Headache Disorders, Third Edition (ICHD-3), defined as headache occurring on ≥15 days per month for more than 3 months, with migraine features present on at least 8 days per month.\n\nHistory of migraine for at least 12 months prior to enrolment. Experiencing chronic migraine during the previous three months, confirmed through clinical history and\u002For headache diary.\n\nPresence of cervical sensorimotor impairment, demonstrated by at least one of the following:\n\nIncreased cervical joint position error. Reduced cervical range of motion. Impaired cervical motor control. Neck pain or cervical dysfunction associated with migraine.\n\nExclusion Criteria:\n\n* • Diagnosis of headache disorders other than chronic migraine (e.g., cervicogenic headache, cluster headache, or medication-overuse headache).\n\nPrevious cervical spine surgery, fracture, or significant cervical trauma. Cervical radiculopathy, myelopathy, or severe cervical spine pathology. Neurological disorders other than migraine (e.g., stroke, multiple sclerosis, Parkinson's disease).\n\nVestibular disorders affecting balance or proprioception. Inflammatory or systemic musculoskeletal diseases (e.g., rheumatoid arthritis, ankylosing spondylitis).\n\nPregnancy or breastfeeding. Physiotherapy, chiropractic treatment, acupuncture, or cervical rehabilitation within the previous 3 months.\n\nBotulinum toxin injections or cervical pain interventions within the previous 3-4 months.\n\nChanges in migraine preventive medication within the previous 4 weeks. Skin conditions preventing surface EMG electrode placement. Inability to comply with the study protocol or provide informed consent.",true,"55 Years",{"count":5,"type":22},[25],"To investigate the effectiveness of mechanism-based cervical sensorimotor rehabilitation on cervical muscle activation, cervical proprioception, and migraine burden.",[55],"Chronic Migraine",[57,58,59,60],"Cervical Sensorimotor Rehabilitation","Joint Position Error","Cervical Muscle Activation","EMG","NOT_YET_RECRUITING",{"date":63,"type":33},"2026-08-18",{"date":65,"type":22},"2026-08-25",{"date":67,"type":22},"2027-03-01",{"name":39,"class":40},{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":41},"100652101","effect-of-nebulized-dexmedetomidine-on-central-sensitization-and-chronification-in-migraine-100652101","NCT07769255","Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine","Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine: A Randomized Controlled Trial Using Calcitonin Gene Related Peptide and Trigeminal Neurophysiological Biomarkers","Inclusion Criteria:\n\n* Diagnosis of Early chronic migraine (\\\u003C6 months of ≥15 headache days\u002Fmonth), per ICHD-3 criteria.\n* No preventive migraine therapy in the prior 8 weeks.\n\nExclusion Criteria:\n\n* Presence of cardiopulmonary, psychiatric, or neurological comorbidities.\n* Current use of sedatives, opioids, or CGRP-targeting therapies.\n* Pregnancy or breastfeeding.",{"count":77,"type":22},146,[25],"Migraine is a debilitating neurological disorder characterized by recurrent headaches episodes, often accompanied by amplified perception of multiple sensory inputs such as cutaneous allodynia, photophobia, and phonophobia. The suggested mechanism in migraine is likely through sensitized trigeminovascular and dysfunctional pain modulatory systems.\n\nDexmedetomidine, a selective α2-adrenergic receptor agonist, exerts central antinociceptive effects by reducing neuronal hyperexcitability, glial activation, and CGRP expression. Nebulized administration provides a non-invasive alternative to intravenous use, with rapid CNS absorption and minimal sedation .",[55],"2026-08-12",{"date":30,"type":33},{"date":84,"type":22},"2026-09-01",{"date":86,"type":22},"2027-03-10",{"name":39,"class":40},{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100651438","title-of-the-research-effect-of-manual-lymphatic-drainage-massage-combined-with-therapeutic-exercises-on-lower-limbs-edema-during-late-pregnancy-100651438","NCT07761741","Title of the Research: Effect of Manual Lymphatic Drainage Massage Combined With Therapeutic Exercises On Lower Limbs Edema During Late Pregnancy","Title of the Research: Effect of Manual Lymphatic Drainage Massage Combined With Therapeutic Exercises On Lower Limbs Edema During Late Pregnancy: A Randomized Clinical Trial","Inclusion Criteria:\n\n* a total of 60 women will be recruited from the Antenatal Clinic of Beni-Suef University Hospital, Beni-Suef, Egypt. Their ages will be ranged from 25-35 years and their body mass index (BMI) will be ranged from 30-35 kg\u002Fm2. All participants are pregnant women at 3rd trimester of pregnancy 28-32 weeks' of gestation diagnosed with late pregnancy physiological lower limbs edema\n\nExclusion Criteria:\n\n* Women will be excluded from the study, if they were diagnosed with any risk pregnancy conditions such as pre-eclampsia, heart diseases, gestational diabetes mellitus respiratory diseases causing excessive coughing or sneezing, chronic physical or mental illness, other pain conditions, coagulation disturbances, had any medical condition that would or failed to complete an informed consent form.","FEMALE","25 Years","35 Years",{"count":99,"type":22},60,[25],"Objective of the study is to investigate the effect of adding manual lymphatic drainage massage to classical therapeutic exercises on resolving physiological lower limbs edema in late pregnancy women. The main question to be answered by this study: Does adding manual lymphatic drainage massage to classical therapeutic exercises have effect on resolving physiological lower limbs edema in late pregnancy ? Researchers will compare 2 groups of 60 participants group A (study group) will include participants who will join a physiotherapy plan of care in the form of sessions compose of manual lymphatic drainage massage technique with specific therapeutic exercise as well as wearing compression garments and advice. While, group B will involve control participants who will follow routine care and advice as well as wearing the same compression garments as group A participants.",[103],"Pregnancy Complication","2026-08-08",{"date":81,"type":33},{"date":104,"type":22},{"date":108,"type":22},"2026-10-15",{"name":39,"class":40},{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":17,"minAge":117,"maxAge":19,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":130,"locationsCount":41},"100631885","cardiac-rehabilitation-in-decompensated-heart-failure-100631885","NCT07506499","Cardiac Rehabilitation in Decompensated Heart Failure","Effect of Cardiac Rehabilitation in Patients With Decompensated Heart Failure","Inclusion Criteria:\n\n* Aged from 45 to 65 years old\n* Both sexes\n* Hospitalized heart failure patients with ejection fraction \\\u003C 40%\n* Conscious and cooperative\n* Able to participate in training actively\n\nExclusion Criteria:\n\n* Acute major cardiovascular events (e.g., acute coronary syndrome, stroke, or pulmonary embolism)\n* Uncontrolled life-threatening arrhythmias\n* Severe valvular heart disease requiring urgent surgery\n* Pregnancy\n* End-stage renal disease requiring dialysis\n* Significant pulmonary diseases such as pulmonary arterial hypertension,\n* Implanted pacemaker\n* Clinically significant peripheral vascular disease\n* Severe anemia\n* Exercise-induced angina or ST-segment changes","45 Years",{"count":119,"type":22},135,[25],"Heart failure is a common clinical condition that often leads to reduced exercise tolerance, shortness of breath, and poor quality of life. Many patients with heart failure also develop weakness of the inspiratory muscles, which contributes to limited physical activity and worsening functional capacity. Inspiratory muscle training (IMT) has been suggested as a useful rehabilitation method to improve respiratory muscle strength and exercise tolerance. In addition, functional electrical stimulation (FES) of the lower limb muscles may help activate skeletal muscles and improve functional performance in patients who cannot tolerate conventional exercise.\n\nThis randomized controlled study aims to investigate the effect of combining inspiratory muscle training with functional electrical stimulation of the lower limbs in patients with decompensated heart failure. A total of 135 hospitalized patients with decompensated heart failure will be recruited from the Cardiology Department at Beni-Suef University Hospital and randomly assigned into three groups. Group A (45 patients) will receive routine medical treatment in addition to inspiratory muscle training combined with functional electrical stimulation. Group B (45 patients) will receive routine medical treatment with inspiratory muscle training only. Group C (45 patients) will receive routine medical treatment alone.\n\nThe intervention will start during hospitalization and will continue for four weeks. The study will evaluate the effects of these interventions on cardiac function, inspiratory muscle strength, and functional capacity as primary outcomes. Secondary outcomes will include dyspnea severity, quality of life, heart rate, oxygen saturation, hand grip strength, and maximum expiratory pressure. The findings of this study may help clarify the potential role of combining inspiratory muscle training with functional electrical stimulation as part of cardiac rehabilitation in patients with decompensated heart failure.",[123],"Decompensated Heart Failure","2026-08-04",{"date":126,"type":33},"2026-08-06",{"date":128,"type":33},"2026-04-01",{"date":84,"type":22},{"name":39,"class":40},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":17,"minAge":139,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":41},"100642342","frequency-rhythmic-electrical-modulated-stimulation-effect-in-peripheral-neuropathy-patients-severity-of-cases-and-qol-100642342","NCT07645482","Frequency Rhythmic Electrical Modulated Stimulation Effect in Peripheral Neuropathy Patients Severity of Cases and Qol.","Effects Of Frequency Rhythmic Electrical Modulated Stimulation (FREMS) On Blood Perfusion, Neuropathy Severity And Quality Of Life In Diabetic Patients With Peripheral Neuropathy And Lower Limb Ischemia: A Randomized Controlled Trial.","FREMS","Inclusion Criteria:\n\n* patients diagnosed with DM\n* patients age group above 40 years old.\n* patient diagnosed with peripheral neuropathy with symptoms lasts more than 3 months.\n* patients lower limb ischemia in duplex affected APSV.\n\nExclusion Criteria:\n\n* patients with implant peacemakers, defibrillator, or neurostimulator.\n* pregnancy.\n* any severe disease prevent compliance to study procedures.\n* patients with disabilities prevent their commitment to sessions.","40 Years",{"count":141,"type":22},40,[25],"It's estimated that 50% of diabetic patients will have peripheral neuropathy as a complication within 3 years of the diabetes incidence \\[14\\], the goal of the study is to investigate this problem through the following objectives:\n\n1. To measure the effect of using FREMS therapy in diabetic neuropathy in interventional group on the blood perfusion, neuropathy severity and quality of life after 10 sessions compared to baseline.\n2. To measure the effect of using standard of care in diabetic neuropathy in control group on the blood perfusion, neuropathy severity and quality of life after 10 sessions compared to baseline.\n3. To compare the results between both interventional and control group.",[145],"Peripheral Neuropathy With Type 2 Diabetes","2026-07-19",{"date":148,"type":33},"2026-07-21",{"date":150,"type":22},"2026-07",{"date":152,"type":22},"2026-08",{"name":39,"class":40},{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":41},"100643528","phase-4-evaluation-of-the-clinical-impact-of-adjunctive-l-carnitine-therapy-in-critically-ill-hepatic-patients-admitted-to-intensive-care-unit-100643528","NCT07642076","Evaluation of the Clinical Impact of Adjunctive L-carnitine Therapy in Critically Ill Hepatic Patients Admitted to Intensive Care Unit","Inclusion Criteria:\n\n* Age more than 18 years old\n* male or female with confirmed liver disease admitted to intensive care unit, including:\n* Acute-on-chronic liver failure (ACLF)\n* Hepatic encephalopathy\n* spontaneous bacterial peritonitis (SBP)\n* variceal bleeding\n* fulminant hepatitis\n* Hepatorenal syndrome\n* Ascites\n* Etc\n\nExclusion Criteria:\n\n* Age of less than 18 years old\n* Pregnancy or Lactation\n* patients have seizure\n* patient on warfarin",{"count":161,"type":22},58,[163],"PHASE4","This study aims to evaluate the possible efficacy of l-carnitine in critically ill hepatic patients admitted to intensive care unit.",[166],"Hepatic","2026-07-18",{"date":148,"type":33},{"date":170,"type":22},"2026-06",{"date":172,"type":22},"2027-03",{"name":39,"class":40},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":139,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":191,"leadSponsor":193,"locationsCount":41},"100647678","comparative-impact-of-integrated-neuromuscular-inhibition-technique-dry-cupping-and-dry-needling-on-mechanical-neck-pain-a-randomized-controlled-trial-100647678","NCT07711041","Comparative Impact of Integrated Neuromuscular Inhibition Technique, Dry Cupping and Dry Needling on Mechanical Neck Pain; A Randomized Controlled Trial","Inclusion Criteria:\n\n* Medically competent men and women will be included They had chronic MTrPs in the upper trapezius for more than 6 months Diagnostic criteria of being a tight band with a palpable nodule and distant pain when subjected to pressure\n\nExclusion Criteria:\n\n* subjects with previous neck or shoulder pathology (e.g., fracture, sur¬gery, inflammatory and infectious diseases), cervical disc pathology, systemic disorder, fibromyalgia, those who underwent physical therapy for at least the previous 3 months",{"count":5,"type":22},[25],"This study ill include four treatment groups. Group A who will receive traditional physical therapy, group B who will receive INIT plus traditional physical therapy , group C who will receive dry cupping therapy plus traditional physical therapy or group D will receive Dry needling therapy plus traditional physical therapy . All groups completed 4 weeks of intervention.",[184,185,186],"Mechanical Neck Pain","Dry Needling Technique","Dry Cupping Technique","2026-07-14",{"date":189,"type":33},"2026-07-17",{"date":150,"type":22},{"date":192,"type":22},"2027-05",{"name":39,"class":40},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":17,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":204,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":4},"100646087","kinesio-taping-versus-electrical-stimulation-on-dysphagia-in-bilateral-cerebral-palsy-100646087","NCT07695350","Kinesio Taping Versus Electrical Stimulation on Dysphagia in Bilateral Cerebral Palsy","Kinesio Taping Versus Neuromuscular Electrical Stimulation on Dysphagia in Children With Bilateral Spastic Cerebral Palsy. A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children ages will be ranged from 3 to 7 years old.\n* They scored ≤10 on an initial evaluation of Oral Motor Assessment scale.\n* They scored from 5 to 7 in accordance to dysphagia severity scale.\n* Sufficient cognition to follow simple verbal instructions.\n\nExclusion Criteria:\n\n* Congenital problems of mouth and soft plate (e.g: cleft lip and plate).\n* Jaw anomalies.\n* Gum and\u002For dental problems.\n* Chest infection or unstable cardiopulmonary conditions.\n* Uncontrolled seizures.\n* History of recent surgery or trauma affecting the head, neck, or oral region.\n* Skin allergies that prevent the application of kinesio-tape or electrical stimulation electrodes.","3 Years","7 Years",{"count":99,"type":22},[25],"The purpose of this study will be to compare the effect between kinesiotaping and neuromuscular electrical stimulation on dysphagia in children with bilateral spastic cerebral palsy.",[207],"Bilateral Spastic Cerebral Palsy",[209,210,211,212],"Kinesio Taping","Electrical Stimulation","Dysphagia","Bilateral Cerebral Palsy","2026-07-06",{"date":215,"type":33},"2026-07-10",{"date":217,"type":22},"2026-07-12",{"date":219,"type":22},"2026-10-12",{"name":39,"class":40},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":238,"leadSponsor":240,"locationsCount":41},"100646922","phase-2-exploring-the-potential-benefits-of-using-dapagliflozin-in-cirrhotic-chronic-liver-disease-patients--a-randomized-controlled-trial-100646922","NCT07684326","\"Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial\"","Inclusion Criteria:\n\n* Adult patients 18 years of age and older with a diagnosis of liver cirrhosis with any degree of ascites that led to previous or recent hospital admission (determined by clinical findings and imaging) will be included in the study.\n\nExclusion Criteria:\n\n1. Child Pugh score ≥ 12 or MELD score \\> 25.\n2. Previous history of hypoglycemia or has a previous history of DKA.\n3. Blood pressure less than 90\u002F60 or need dose of midodrine \\>15 mg\u002Fday.\n4. Previous history of recurrent urinary tract infections (more than 2 infections in the last 6 months) or anatomic urologic defects that predispose to urinary tract infection.\n5. Pregnant or lactating female patients.\n6. Hypersensitivity to dapagliflozin.\n7. eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2\n8. Had hepatocellular carcinoma or any malignancy.\n9. Serum sodium level \\\u003C 125 mg\u002Fdl.\n10. Portal vein thrombosis.",{"count":228,"type":22},52,[230,231],"PHASE2","PHASE3","This study aims to evaluate beneficial effects of using dapagliflozin in cirrhotic chronic liver disease patients. We hypnotized that the use of dapagliflozin will be associated with fewer need for large volume paracentesis hence better control of ascites, fewer need for ICU admissions, improvement of patient quality of life, better healthcare cost saving and reduced mortality rate.",[234],"Ascites Hepatic","2026-06-29",{"date":213,"type":33},{"date":150,"type":22},{"date":239,"type":22},"2027-09",{"name":39,"class":40},{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":49,"sex":17,"minAge":248,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":41},"100644159","outcomes-of-ridge-splitting-versus-sausage-technique-100644159","NCT07664605","Outcomes of Ridge Splitting Versus Sausage Technique","Outcomes Of Ridge Splitting Versus Sausage Technique With Simultaneous Implant Placement For Augmenting Mandibular Horizontal Bone Defects.","Inclusion Criteria:\n\n1. Patients with deficient bone volume between (2 : 3.5 ) mm\n2. Patients must have installed functional implant for no less than 3 months- enough time to allow for bone augmentation changes.\n3. Patients with no defect in the gingival tissues.\n4. Patients with un-remarkable medical compromising conditions\n5. Patients with good oral hygiene at time of the examination\n\nExclusion Criteria:\n\n1. Patients with compromising medical condition.\n2. Patients with severe bone resorption.\n3. Patients with D1 or D2 bone.\n4. Bone height \\\u003C10mm","20 Years","75 Years",{"count":251,"type":22},30,[25],"The current study aims to increase the width of the alveolar bone in defective mandibular ridge with simultaneous implant placement and enhance the implant stability",[255],"Bone Loss, Alveolar","2026-06-20",{"date":258,"type":33},"2026-06-24",{"date":260,"type":22},"2026-06-01",{"date":262,"type":22},"2026-12-01",{"name":39,"class":40},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":249,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":283,"locationsCount":41},"100507272","efficacy-of-ultrasound-guided-pifb-versus-lidocaine-infusion-on-postoperative-pain-after-sternotomy-100507272","NCT05885230","Efficacy of Ultrasound Guided PIFB Versus Lidocaine Infusion on Postoperative Pain After Sternotomy","The Efficacy of Ultrasound-guided Pecto-Intercostal Fascial Plain Block Versus Lidocaine Infusion on Acute and Chronic Post-sternotomy Pain; A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n1. age between 18 and 75 years.\n2. patient scheduled to undergo elective on-pump cardiac surgery with sternotomy.\n3. American Society of Anesthesiologists classification of physical status \\\u003C IV.\n\nExclusion Criteria:\n\n1. emergency surgery.\n2. off-pump surgery.\n3. redo surgery.\n4. ejection fraction less than 35%.\n5. refusal of the patient.\n6. known hypersensitivity to LA.\n7. chronic opioid use or chronic pain patient.\n8. psychiatric problems or communication difficulties.\n9. liver insufficiency (defined as a serum bilirubin ≥ 34 μmol\u002Fl, albumin ≤ 35 g\u002Fdl, INR ≥ 1.7).\n10. renal insufficiency (defined as a glomerular filtration rate \\\u003C 44 ml\u002Fmin).\n11. obstructive sleep apnea syndrom.\n12. coexisting hematologic disorders.\n13. pregnancy or breastfeeding.",{"count":272,"type":22},138,[25],"Chronic pain is a common complication after cardiothoracic surgery. The prevalence of post-sternoyomy pain syndrome (PSPS) ranges from 33% to 91%. Exact pathogenetic mechanisms for developing chronic pain after sternotomy are unknown. Apart from intraoperative nerve damage and subsequent postoperative neuropathic pain, operation techniques, age, sex, pre-existing pain, genetic and psychosocial factors, severe postoperative pain, and analgesic management are suspected to have an impact on the development of PSPS .",[276],"Cardiac Surgery","2026-06-18",{"date":279,"type":33},"2026-06-23",{"date":281,"type":33},"2023-05-01",{"date":192,"type":22},{"name":39,"class":40},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":299,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":41},"100642198","suprapubic-drainage-during-transurethral-cystolithotripsy-for-large-bladder-stones-100642198","NCT07642440","Suprapubic Drainage During Transurethral Cystolithotripsy for Large Bladder Stones","Transurethral Cystolithotripsy With Versus Without Adjunctive Suprapubic Tube Drainage for Bladder Stones >2 cm: A Prospective Randomized Controlled Trial","SPT-CYSTO Tria","Inclusion Criteria:\n\n* Age 18 years or older.\n* Radiologically confirmed bladder stone with maximum diameter greater than 2 cm.\n* Scheduled for elective transurethral cystolithotripsy.\n* Sterile urine culture before surgery, or adequately treated urinary tract infection according to culture sensitivity.\n* Fit for spinal or general anesthesia.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Urethral stricture preventing safe cystoscopic access.\n* Active uncontrolled urinary tract infection or sepsis.\n* Neurogenic bladder with severely impaired bladder emptying requiring chronic catheterization.\n* History of bladder cancer or suspected bladder tumor requiring simultaneous transurethral resection of bladder tumor.\n* Coagulopathy or uncorrected bleeding tendency.\n* Patients requiring concomitant transurethral resection of the prostate, Holmium laser enucleation of the prostate, or other prostate surgery in the same session.\n* Previous pelvic radiotherapy or major lower urinary tract reconstruction.\n* Pregnancy.\n* Refusal to participate.",{"count":293,"type":22},140,[25],"Bladder stones larger than 2 cm are commonly treated by endoscopic fragmentation through the urethra. During transurethral cystolithotripsy for large stones, the procedure may be prolonged because of poor visibility, stone dust, bladder overdistension, and repeated need for irrigation or evacuation.\n\nThis randomized controlled trial will compare standal Holmium:YAG laser cystolithotripsy using a 17 Fr cystoscope sheath with the same procedure plus an adjunctive 8 Fr suprapubic catheter used only for bladder drainage during the operation. The suprapubic catheter will not be used for stone fragmentation or stone extraction.\n\nThe main outcome will be total operative time. Secondary outcomes will include fragmentation and clearance time, laser activation time, total laser energy, irrigation volume, visibility-related interruptions, stone-free rate at 30 days, complications, catheter duration, postoperative pain, and hospital stay.",[297,298],"Bladder Stone","Cystolithiasis",[300,301,302],"Transurethral cystolithotripsy","Suprapubic drainage","Suprapubic catheter","2026-06-15",{"date":305,"type":33},"2026-06-16",{"date":307,"type":33},"2026-06-08",{"date":309,"type":22},"2028-06",{"name":39,"class":40},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":319,"minAge":320,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":324,"conditions":325,"keywords":329,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":338,"leadSponsor":340,"locationsCount":41},"100641769","phase-4-tamsulosin-with-or-without-tadalafil-for-trial-without-catheter-after-acute-urinary-retention-due-to-benign-prostatic-hyperplasia-100641769","NCT07654413","Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia","Tamsulosin With Versus Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia: A Prospective Double-Blind Randomized Trial","TAMS-TAD-TWOC","Inclusion Criteria:\n\n* Male patient aged 50 years or older.\n* First episode of spontaneous painful acute urinary retention.\n* Successful urethral catheterization at presentation.\n* Drained urine volume at presentation of at least 300 mL.\n* Clinical impression of benign prostatic obstruction or benign prostatic hyperplasia based on history, digital rectal examination, and\u002For ultrasound evidence of enlarged prostate.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Previous episode of acute urinary retention.\n* Chronic painless urinary retention phenotype.\n* Active urinary tract infection or sepsis.\n* Gross hematuria with clot retention.\n* Suspected or known urethral stricture.\n* Neurogenic bladder or major neurologic disease affecting voiding.\n* History of prostate cancer or bladder cancer.\n* Previous prostate surgery.\n* Current use of nitrates or guanylate cyclase stimulators.\n* Contraindication to tadalafil or tamsulosin.\n* Severe hypotension or unstable cardiovascular disease.\n* Severe renal impairment.\n* Severe hepatic impairment.\n* Current or recent use of phosphodiesterase type 5 inhibitors before enrollment.","MALE","50 Years",{"count":322,"type":22},320,[163],"Acute urinary retention is a common emergency in men with benign prostatic hyperplasia. After bladder drainage with a urethral catheter, patients usually undergo a trial without catheter to determine whether they can pass urine again without recatheterization.\n\nThis study will evaluate whether adding tadalafil 5 mg once daily to tamsulosin 0.4 mg once daily improves the chance of successful trial without catheter in men with first-episode acute urinary retention due to presumed benign prostatic hyperplasia.\n\nParticipants will be randomly assigned to receive either tamsulosin plus tadalafil or tamsulosin plus a matching placebo. Study medication will start within 24 hours after catheterization. The catheter will be removed on Day 7. If the first trial without catheter fails, the catheter will be reinserted and a second rescue trial without catheter will be performed on Day 14.\n\nThe main outcome is overall catheter-free success by Day 14. Participants will also be followed for recurrent urinary retention, post-void residual urine, urinary flow, catheter-related complications, drug-related adverse events, and the need for benign prostatic hyperplasia-related surgery within 3 months.",[326,327,328],"Acute Urinary Retention","Benign Prostatic Hyperplasia","Benign Prostatic Obstruction",[330,331,332,333,327],"Trial Without Catheter","TWOC","Tamsulosin","Tadalafil","2026-06-12",{"date":336,"type":33},"2026-06-17",{"date":307,"type":33},{"date":339,"type":22},"2027-12",{"name":39,"class":40},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":319,"minAge":18,"maxAge":117,"enrollmentInfo":348,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":350,"conditions":351,"keywords":354,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":361,"leadSponsor":362,"locationsCount":41},"100642491","single-infrapubic-versus-bilateral-subinguinal-microsurgical-varicocelectomy-100642491","NCT07650955","Single Infrapubic Versus Bilateral Subinguinal Microsurgical Varicocelectomy","Single Infrapubic Versus Bilateral Subinguinal Approaches for Bilateral Microsurgical Varicocelectomy: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Male patients aged 18 to 45 years.\n* Clinically palpable bilateral varicocele, grade II or grade III.\n* Diagnosis confirmed by color Doppler ultrasound.\n* Infertility for at least 12 months and\u002For abnormal semen analysis.\n* Female partner evaluation performed or planned to exclude major uncorrected female-factor infertility.\n* Patient fit for surgery and anesthesia.\n* Written informed consent provided by the participant.\n\nExclusion Criteria:\n\n* Subclinical varicocele detected only by Doppler ultrasound.\n* Unilateral varicocele.\n* Recurrent varicocele after previous surgery, embolization, or sclerotherapy.\n* Previous inguinal, scrotal, pelvic, or penile surgery likely to distort surgical anatomy.\n* Associated inguinal hernia, hydrocele, spermatocele, epididymal cyst, or other scrotal condition requiring simultaneous surgery.\n* Azoospermia, especially suspected non-obstructive azoospermia.\n* Active urinary tract or genital infection.\n* Coagulopathy or anticoagulant therapy that cannot be safely interrupted.\n* Severe obesity, defined as body mass index greater than 40 kg\u002Fm², or any anatomical condition preventing safe exposure by either surgical approach.\n* Refusal to participate or inability to complete follow-up.",{"count":141,"type":22},[25],"Bilateral varicocele is commonly treated by microsurgical varicocelectomy. The conventional bilateral subinguinal approach usually requires two separate skin incisions, one on each side. A single midline infrapubic approach may allow bilateral microsurgical repair through one incision and may reduce access-related morbidity.\n\nThis prospective randomized controlled trial will compare single infrapubic microsurgical bilateral varicocelectomy with conventional bilateral subinguinal microsurgical varicocelectomy in adult men with clinically palpable bilateral varicocele. The study will evaluate postoperative pain, analgesic requirement, time to return to normal daily activity, operative time, scar satisfaction, wound complications, recurrence, and other safety outcomes during follow-up.",[352,353],"Bilateral Varicocele","Male Infertility",[355,356,357],"Microsurgical varicocelectomy","Single infrapubic approach","Bilateral varicocele","2026-06-11",{"date":305,"type":33},{"date":307,"type":33},{"date":192,"type":22},{"name":39,"class":40},{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":319,"minAge":320,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":23,"phases":372,"briefSummary":373,"conditions":374,"keywords":375,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":380,"leadSponsor":382,"locationsCount":41},"100642454","phase-4-tamsulosin-dose-escalation-or-silodosin-switch-before-trial-without-catheter-in-bph-related-acute-urinary-retention-100642454","NCT07650968","Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention","Tamsulosin 0.4 mg Continuation Versus Dose Escalation to 0.8 mg Versus Switch to Silodosin 8 mg for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Male patients aged 50 years or older.\n* Acute urinary retention requiring urethral catheterization.\n* Presumed acute urinary retention secondary to benign prostatic enlargement or benign prostatic obstruction.\n* Already receiving tamsulosin 0.4 mg once daily for at least 4 weeks before the acute urinary retention episode.\n* Successful urethral catheterization at presentation.\n* Initial catheterized urine volume ≤1000 mL, with a clinical presentation consistent with painful acute urinary retention.\n* Prostate enlargement on ultrasound or clinical assessment consistent with benign prostatic hyperplasia or benign prostatic obstruction.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Known or suspected prostate cancer.\n* Previous prostate surgery.\n* Previous urethral stricture disease or urethral surgery.\n* Neurogenic bladder or known neurological disease affecting voiding.\n* Chronic urinary retention rather than acute painful retention.\n* Acute urinary retention due to non-BPH causes, including clot retention, bladder stone obstruction, acute prostatitis, urethral trauma, or drug-induced retention.\n* Severe urinary tract infection, sepsis, or fever at presentation.\n* Gross hematuria requiring irrigation.\n* Failed urethral catheterization or need for suprapubic catheterization.\n* Current use of silodosin, alfuzosin, doxazosin, terazosin, tadalafil, anticholinergics, beta-3 agonists, or other drugs that may significantly affect voiding.\n* Severe renal impairment requiring urgent intervention.\n* Symptomatic postural hypotension or recurrent syncope.\n* Known hypersensitivity to silodosin.\n* Severe hepatic impairment.\n* Inability to comply with follow-up.",{"count":371,"type":22},378,[163],"This randomized controlled trial will compare three medication strategies before trial without catheter in men with acute urinary retention due to benign prostatic hyperplasia who were already taking tamsulosin 0.4 mg once daily before the retention episode. After urethral catheterization, eligible participants will be randomly assigned to one of three groups for 7 days: continuation of tamsulosin 0.4 mg once daily, escalation to tamsulosin 0.8 mg once daily, or switching to silodosin 8 mg once daily. The urethral catheter will be removed on Day 7, and the ability to void successfully without re-catheterization will be assessed. Follow-up will continue to Day 30, with additional recording of catheter-free status, recurrent urinary retention, urinary flow, post-void residual urine, symptom scores, adverse drug events, catheter-related complications, and the need for later benign prostatic hyperplasia-related surgery.",[326,327],[330,332,376,377],"Silodosin","Catheter-free status",{"date":305,"type":33},{"date":307,"type":33},{"date":381,"type":22},"2027-06",{"name":39,"class":40},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":319,"minAge":320,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":23,"phases":393,"briefSummary":394,"conditions":395,"keywords":398,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":405,"leadSponsor":406,"locationsCount":41},"100642693","water-vapor-thermal-therapy-versus-ejaculation-sparing-bipolar-transurethral-enucleation-for-benign-prostatic-hyperplasia-100642693","NCT07648888","Water Vapor Thermal Therapy Versus Ejaculation-Sparing Bipolar Transurethral Enucleation for Benign Prostatic Hyperplasia","Water Vapor Thermal Therapy Versus Ejaculation-Sparing Bipolar Transurethral Enucleation of the Prostate for Benign Prostatic Hyperplasia: A Prospective Comparative Study","REZ-ESBTUEP","Inclusion Criteria:\n\n* Male patients aged 50 years or older.\n* Symptomatic benign prostatic hyperplasia with moderate-to-severe lower urinary tract symptoms.\n* International Prostate Symptom Score (IPSS) 13 or higher.\n* Prostate volume 30 to 80 mL measured by transrectal ultrasound.\n* Maximum urinary flow rate (Qmax) 15 mL\u002Fs or less with voided volume 150 mL or more.\n* Post-void residual urine volume 250 mL or less.\n* Failed, intolerant, or unwilling to continue medical therapy for benign prostatic hyperplasia.\n* Sexually active within the previous 3 months.\n* Preserved antegrade ejaculation at baseline.\n* Patient wishes to preserve ejaculation.\n* Ability to complete the International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form (MSHQ-EjD-SF).\n* Written informed consent.\n\nExclusion Criteria:\n\n* Suspected or confirmed prostate cancer.\n* Abnormal prostate-specific antigen or digital rectal examination suspicious for malignancy unless prostate cancer has been excluded according to standard clinical practice.\n* Previous prostate surgery.\n* Previous urethral surgery likely to affect instrumentation or study outcomes.\n* Urethral stricture disease.\n* Neurogenic bladder dysfunction.\n* Active urinary tract infection until adequately treated.\n* Bladder stones requiring concomitant surgery.\n* Prostate volume less than 30 mL or more than 80 mL.\n* Baseline anejaculation or severe ejaculatory dysfunction.\n* No sexual activity during the previous 3 months.\n* Chronic indwelling urethral or suprapubic catheter.\n* Recurrent urinary retention or suspected detrusor underactivity requiring urodynamic clarification.\n* Post-void residual urine volume more than 250 mL.\n* Uncontrolled coagulopathy.\n* Anticoagulation or antiplatelet therapy that cannot be safely managed perioperatively.\n* Unfitness for anesthesia or intervention.\n* Inability or unwillingness to comply with follow-up.",{"count":392,"type":22},120,[25],"This prospective comparative study will evaluate Water Vapor Thermal Therapy (WVTT\u002FRezum) versus Ejaculation-Sparing Bipolar Transurethral Enucleation of the Prostate (ES-B-TUEP) in sexually active men with symptomatic benign prostatic hyperplasia.\n\nEligible patients will have moderate-to-severe lower urinary tract symptoms, preserved antegrade ejaculation at baseline, and will be candidates for procedural treatment after failure, intolerance, or unwillingness to continue medical therapy. This is not a randomized study. Treatment selection will be based on shared decision-making between the patient and the treating surgeon after standardized counseling about both procedures.\n\nThe study will compare ejaculatory function, urinary symptom improvement, urinary flow, post-void residual urine, erectile function, perioperative outcomes, complications, catheterization duration, hospital stay, medication restart, and retreatment or reintervention during follow-up. The primary outcome will be the change in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form Function domain score from baseline to 12 months.",[327,396,397],"Lower Urinary Tract Symptoms","Ejaculatory Dysfunction",[399,400,401],"Water Vapor Thermal Therapy","Ejaculation-Sparing","MSHQ-EjD-SF","2026-06-10",{"date":303,"type":33},{"date":307,"type":33},{"date":339,"type":22},{"name":39,"class":40},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":319,"minAge":414,"maxAge":415,"enrollmentInfo":416,"targetDuration":4,"studyType":23,"phases":418,"briefSummary":419,"conditions":420,"keywords":422,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":427,"leadSponsor":429,"locationsCount":41},"100642391","phase-4-l-citrulline-and-tadalafil-for-mild-to-moderate-erectile-dysfunction-100642391","NCT07642505","L-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction","L-Citrulline Versus Tadalafil Versus Combination Therapy in Mild to Moderate Erectile Dysfunction: A Prospective Randomized Trial","Inclusion Criteria:\n\n* Male patients aged 30 to 70 years.\n* Erectile dysfunction for at least 3 months.\n* Mild to moderate erectile dysfunction, defined by International Index of Erectile Function-Erectile Function domain score from 11 to 25.\n* Stable sexual relationship during the study period.\n* Willingness to attempt sexual activity during the study period.\n* Ability to complete study questionnaires and attend follow-up visits.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Severe erectile dysfunction, defined by International Index of Erectile Function-Erectile Function domain score of 10 or less.\n* Current nitrate or nicorandil use.\n* Contraindication or hypersensitivity to tadalafil or L-citrulline.\n* Unstable cardiovascular disease, unstable angina, recent myocardial infarction or stroke, uncontrolled hypertension, or high-risk arrhythmia.\n* Severe hepatic impairment.\n* Severe renal impairment.\n* Untreated hypogonadism requiring hormonal treatment.\n* Hyperprolactinemia or uncontrolled endocrine disorder.\n* Major neurogenic erectile dysfunction, spinal cord injury, or previous radical pelvic surgery causing severe erectile dysfunction.\n* Significant Peyronie's disease preventing intercourse.\n* Active major psychiatric illness impairing reliable assessment.\n* Use of phosphodiesterase type 5 inhibitors, intracavernosal injection therapy, vacuum device therapy, testosterone therapy, L-arginine, L-citrulline, or erectile dysfunction nutraceuticals during the washout period before randomization.\n* Participation in another clinical trial during the previous 3 months.","30 Years","70 Years",{"count":417,"type":22},133,[163],"Erectile dysfunction is a common male sexual health problem that may affect quality of life and sexual relationships. Tadalafil 5 mg once daily is an established oral treatment for erectile dysfunction. L-citrulline is an oral nitric oxide pathway supplement that may improve erectile function by increasing L-arginine availability.\n\nThis randomized trial will compare three oral treatment regimens in men with mild to moderate erectile dysfunction: L-citrulline 1500 mg\u002Fday, tadalafil 5 mg\u002Fday, and the combination of L-citrulline 1500 mg\u002Fday plus tadalafil 5 mg\u002Fday. Participants will receive treatment for 12 weeks and will be followed at baseline, week 4, week 8, and week 12.\n\nThe primary outcome will be the change in the International Index of Erectile Function-Erectile Function domain score from baseline to 12 weeks. Secondary outcomes will include changes in IIEF-5\u002FSHIM score, Erection Hardness Score, SEP diary outcomes, treatment adherence, adverse events, and treatment discontinuation.",[421],"Erectile Dysfunction",[423,333,424],"L-citrulline","International Index of Erectile Function",{"date":334,"type":33},{"date":307,"type":33},{"date":428,"type":22},"2026-12",{"name":39,"class":40},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":319,"minAge":320,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":23,"phases":438,"briefSummary":439,"conditions":440,"keywords":441,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":445,"startDateStruct":446,"completionDateStruct":447,"leadSponsor":448,"locationsCount":41},"100641924","water-vapor-thermal-therapy-versus-ejaculation-preserving-holep-for-benign-prostatic-hyperplasia-100641924","NCT07648875","Water Vapor Thermal Therapy Versus Ejaculation-Preserving HoLEP for Benign Prostatic Hyperplasia","Water Vapor Thermal Therapy Versus Ejaculation-Preserving Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia: A Prospective Comparative Study","Inclusion Criteria:\n\n* Male patients aged 50 years or older.\n* Symptomatic benign prostatic hyperplasia with moderate-to-severe lower urinary tract symptoms.\n* International Prostate Symptom Score (IPSS) of 13 or higher.\n* Prostate volume 30 to 80 mL measured by transrectal ultrasound.\n* Maximum urinary flow rate (Qmax) of 15 mL\u002Fs or less with voided volume of at least 150 mL.\n* Post-void residual urine volume of 250 mL or less.\n* Failure, intolerance, or unwillingness to continue medical therapy for benign prostatic hyperplasia.\n* Sexually active within the previous 3 months.\n* Preserved antegrade ejaculation at baseline.\n* Patient wishes to preserve ejaculation.\n* Ability to complete the International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF).\n* Written informed consent.\n\nExclusion Criteria:\n\n* Suspected or confirmed prostate cancer.\n* Abnormal prostate-specific antigen or digital rectal examination suspicious for malignancy unless prostate cancer has been excluded according to standard clinical practice.\n* Previous prostate surgery.\n* Previous urethral surgery likely to affect instrumentation or study outcomes.\n* Urethral stricture disease.\n* Neurogenic bladder dysfunction.\n* Active urinary tract infection until adequately treated.\n* Bladder stones requiring concomitant surgery.\n* Prostate volume less than 30 mL or more than 80 mL.\n* Baseline anejaculation or severe ejaculatory dysfunction.\n* No sexual activity during the previous 3 months.\n* Chronic indwelling urethral or suprapubic catheter.\n* Suspected detrusor underactivity requiring urodynamic clarification.\n* Post-void residual urine volume more than 250 mL.\n* Uncontrolled coagulopathy.\n* Anticoagulation or antiplatelet therapy that cannot be safely managed perioperatively.\n* Unfitness for anesthesia or intervention.\n* Inability or unwillingness to comply with follow-up.",{"count":392,"type":22},[25],"This prospective comparative study will evaluate Water Vapor Thermal Therapy (Rezum) versus ejaculation-preserving Holmium Laser Enucleation of the Prostate (EP-HoLEP) in sexually active men with symptomatic benign prostatic hyperplasia and prostate volume 30-80 mL.\n\nEligible patients will not be randomized. The treatment option will be selected through shared decision-making between the patient and treating physician after standardized counseling about the expected benefits, risks, recovery, catheter duration, urinary outcomes, durability, and potential effects on ejaculation and sexual function.\n\nThe main objective is to compare the change in ejaculatory function from baseline to 12 months using the Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF) Function domain. Secondary outcomes will include urinary symptom improvement, quality of life, maximum urinary flow rate, post-void residual urine volume, erectile function, antegrade ejaculation preservation, catheterization duration, hospital stay, complications, restart of benign prostatic hyperplasia medication, and retreatment or reintervention within 12 months.",[327,396],[399,442,443,444],"Rezum","Ejaculation-Preserving HoLEP","Male Sexual Health Questionnaire",{"date":303,"type":33},{"date":307,"type":33},{"date":339,"type":22},{"name":39,"class":40},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":137,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":17,"minAge":139,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":23,"phases":458,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":464,"completionDateStruct":465,"leadSponsor":467,"locationsCount":41},"100643461","frequency-rhythmic-electrical-modulated-stimulation-therapy-in-chronic-ulcers-100643461","NCT07645495","Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.","Chronic Ulcer Healing With Frequency Rhythmic Electrical Modulated Stimulation (FREMS)Therapy and Phenytoin Application in Diabetic Patients.","Inclusion Criteria:\n\n* chronic ulcers more than 3 months.\n\nExclusion Criteria:\n\n* incapable of being in the clinic of diabetic ulcer during treatment period 3 days\u002F week for 3 months.\n* severe ischemia that is indicated for a surgery.\n* infection or osteomyelitis.",{"count":457,"type":22},26,[25],"The goal of the study is to\n\n1. To measure wound size of chronic ulcers after using FREMS therapy and phenytoin application in the interventional group monthly till the end of the third month compared to baseline.\n2. To measure wound size of chronic ulcers after using standard of care in control group monthly till the end of the third month compared to baseline.\n3. To compare the results of the 2 groups and determine the significance of the treatment.",[461],"Chronic Ulcers","2026-06-09",{"date":334,"type":33},{"date":150,"type":22},{"date":466,"type":22},"2026-09",{"name":39,"class":40},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":17,"minAge":475,"maxAge":476,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":478,"briefSummary":479,"conditions":480,"keywords":482,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":489,"leadSponsor":491,"locationsCount":4},"100643550","mat-pilates-exercises-on-balance-in-adolescents-with-scoliosis-100643550","NCT07638826","Mat-Pilates Exercises on Balance in Adolescents With Scoliosis","Efficacy of Mat-Pilates Exercises on Balance and Functional Capacity in Adolescents With Scoliosis. A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Adolescents ages will be ranged from 12 to 15 years old.\n* Cobb's angles ranging from 10° to 25°.\n* Functional Hearing and vision.\n* Independent standing and walking.\n\nExclusion Criteria:\n\n* Either spine, upper, or lower limbs fractures.\n* Leg length discrepancy or foot deformities.\n* Rheumatic and congenital heart disease.\n* History of previous surgical operation.","12 Years","15 Years",{"count":141,"type":22},[25],"The aim of this study is to examine the effects of mat-Pilates exercises on balance and functional capacity in adolescents with scoliosis.",[481],"Adolescents With Scoliosis",[483,484,485],"Pilates Exercises","Biodex","Adolescent Scoliosis","2026-06-05",{"date":402,"type":33},{"date":303,"type":22},{"date":490,"type":22},"2026-09-15",{"name":39,"class":40},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":95,"minAge":500,"maxAge":139,"enrollmentInfo":501,"targetDuration":4,"studyType":23,"phases":503,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":514,"locationsCount":41},"100640120","phase-3-efficacy-of-alpha-lipoic-acid-combined-with-myo-inositol-in-non-diabetic-pcos-patients-100640120","NCT07630779","Efficacy of Alpha Lipoic Acid Combined With Myo-Inositol in Non-Diabetic PCOS Patients","A Randomized Controlled Trial Evaluating the Efficacy of Alpha Lipoic Acid Combined With Myo-Inositol With or Without Metformin in Non-Diabetic Women With Polycystic Ovary Syndrome","ALA-MYO-PCOS","Inclusion Criteria:\n\n* Women aged 21 to 40 years\n* Diagnosed with polycystic ovary syndrome (PCOS) according to Rotterdam criteria\n* Not currently pregnant or lactating\n* No hormonal therapy within the last 3 months\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* \\- History of diabetes mellitus, hypertension, or thyroid disorders\n* History of cardiovascular, renal, or hepatic disease\n* Use of hormonal contraceptives or insulin sensitizers within the last 3 months\n* Known hypersensitivity or allergy to study medications (myo-inositol, alpha-lipoic acid, or metformin)\n* Non-Egyptian ethnicity","21 Years",{"count":502,"type":22},180,[231],"This study evaluates the efficacy of alpha-lipoic acid combined with myo-inositol, with or without metformin, in improving menstrual regularity and ovulation in non-diabetic women with polycystic ovary syndrome (PCOS). The study also assesses metabolic, hormonal, and clinical outcomes.",[506],"Poly Cystic Ovary Syndrome",[508],"PCOS Myo-Inositol Alpha Lipoic Acid Metformin Insulin Resistance Ovulation","2026-06-02",{"date":486,"type":33},{"date":512,"type":33},"2026-03-10",{"date":428,"type":22},{"name":39,"class":40},{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":117,"maxAge":19,"enrollmentInfo":521,"targetDuration":4,"studyType":23,"phases":523,"briefSummary":524,"conditions":525,"keywords":527,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":532,"leadSponsor":533,"locationsCount":41},"100608689","functional-inspiratory-versus-expiratory-muscle-electrical-stimulation-on-weaning-outcomes-in-mechanically-ventilated-patients-100608689","NCT07204821","Functional Inspiratory Versus Expiratory Muscle Electrical Stimulation on Weaning Outcomes in Mechanically Ventilated Patients","Inclusion Criteria:\n\n* All mechanically ventilated patients will be:\n* Their ages range from 45 to 65 years.\n* Their BMI is from 25-29.9kg\u002Fm2.\n* Mechanically ventilated for at least 24 hours.\n* They all have hypoxemic respiratory failure\n* Glasgow coma score (GCS) ranged from 6 to 12.\n* Richmond Agitation-Sedation Scale score: -2 to +2\n* Patients and their relatives had written informed consent.\n\nExclusion Criteria:\n\n* Hemodynamically unstable patients.\n* Patients with rib fractures.\n* Patients with implanted pacemaker.\n* Obese (BMI greater than 30 kgm2).\n* Tachycardia.\n* Uncontrolled hypertension.\n* History of neuromuscular disease at admission.\n* Spinal injuries.\n* Inability to trigger mechanical ventilation\n* Pregnancy\n* An anticipated stay on the ventilator \\\u003C72 h at the time of study\n* Patients who cannot attach electrodes due to local skin damage or infection\n* Patients with Severe intestinal gas accumulation, structural abnormalities, and other reasons that prevent ultrasound detection of diaphragm movement.\n* Congenital myopathies or neuropathies, and contraindications for expiratory muscle FES (cardiac pacemaker, refractory epilepsy, recent (\\\u003C 4 weeks) abdominal surgery).\n* Patients with unrelieved pneumothorax and restricted diaphragm movement disorders.\n* Chest or diaphragm malformation",{"count":522,"type":22},48,[25],"The Goal of This Clinical Trail is\n\n* To find out the difference in the effect of inspiratory muscle functional electrical stimulation and expiratory muscle functional electrical stimulation on weaning outcomes mechanically ventilated patients.\n* To investigate the effect of inspiratory muscle functional electrical stimulation and expiratory muscle functional electrical stimulation on Laboratory investigation (Arterial Blood Gases).\n* To investigate the effect of inspiratory muscle functional electrical stimulation and expiratory muscle functional electrical stimulation on Sonar parameters (Diaphragmatic excursion, Diaphragmatic muscle fractional thickness in the end of inspiration and the end of expiration and abdominal muscles wall thickness). To evaluate the effect of inspiratory muscle functional electrical stimulation and expiratory muscle functional electrical stimulation on (ICU length of stay and Spontaneous Breathing Trail (SBT)).",[526],"Icu",[528],"Functional Inspiratory Muscle Electrical Stimulation, Functional Expiratory Muscle Electrical Stimulation, Weaning Outcomes in Mechanically Ventilated Patients.",{"date":530,"type":33},"2026-06-03",{"date":303,"type":22},{"date":84,"type":22},{"name":39,"class":40},{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":540,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":319,"minAge":320,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":23,"phases":543,"briefSummary":544,"conditions":545,"keywords":546,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":555,"locationsCount":41},"100640142","ejaculation-preserving-versus-standard-bipolar-tuep-for-bph-100640142","NCT07629479","Ejaculation-Preserving Versus Standard Bipolar TUEP for BPH","Bipolar Transurethral Enucleation of the Prostate With Preservation of Ejaculation in Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Trial","EP-BTUEP","Inclusion Criteria:\n\n* Male patients with lower urinary tract symptoms secondary to benign prostatic obstruction after failed medical treatment for at least 3 months.\n* Sexually active patients with a continuous relationship with the same partner.\n* International Prostate Symptom Score of 8 or greater.\n* Transrectal ultrasound-estimated prostate size between 40 and 100 cc.\n* Eligible for bipolar transurethral enucleation of the prostate.\n* Ability to complete the required sexual and urinary function questionnaires.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Preoperative sexual dysfunction.\n* Preoperative ejaculatory dysfunction.\n* Diagnosis or suspicion of prostate cancer.\n* Neurological disorders affecting lower urinary tract or sexual function.\n* Detrusor hypocontractility.\n* Catheter-dependent patients.\n* Patients with bladder stones.\n* Inability or refusal to provide informed consent.",{"count":99,"type":22},[25],"This prospective randomized controlled trial will compare ejaculation-preserving bipolar transurethral enucleation of the prostate with standard bipolar transurethral enucleation of the prostate in sexually active men with benign prostatic hyperplasia and lower urinary tract symptoms after failed medical treatment. Participants will be randomly assigned to either ejaculation-preserving B-TUEP or standard B-TUEP. The study will evaluate preservation of ejaculatory function, erectile function, urinary symptom improvement, uroflowmetry outcomes, post-void residual urine, perioperative complications, and need for retreatment during follow-up.",[327,396,328],[547,548,549,550],"Bipolar transurethral enucleation of the prostate","B-TUEP","Ejaculation preservation","International Prostate Symptom Score",{"date":486,"type":33},{"date":553,"type":33},"2025-09-08",{"date":466,"type":22},{"name":39,"class":40},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":572,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":584},"100640169","initial-drainage-method-and-flexible-ureteroscopy-outcomes-in-calculous-anuria-100640169","NCT07627880","Initial Drainage Method and Flexible Ureteroscopy Outcomes in Calculous Anuria","Impact of Initial Drainage Method on Flexible Ureteroscopy Outcomes in Patients Presenting With Calculous Anuria: A Multicenter Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Calculous anuria secondary to a single upper ureteral stone.\n* Solitary functioning kidney, whether anatomical or functional.\n* Single upper ureteral stone confirmed by non-contrast computed tomography.\n* Stone size from 6 mm to 20 mm in maximum diameter.\n* Patient considered suitable for either initial JJ ureteral stent drainage or percutaneous nephrostomy drainage.\n* Candidate for definitive treatment by flexible ureteroscopy\u002Fretrograde intrarenal surgery.\n* Documented renal functional improvement and clinical stabilization before definitive RIRS.\n* Negative or appropriately treated urine culture before definitive RIRS.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Multiple stones or bilateral stones not fitting the solitary-kidney study design.\n* Renal pelvic, distal ureteral, or multiple ipsilateral stones.\n* Stone burden greater than 20 mm.\n* Septic shock, hemodynamic instability, or need for emergency dialysis at presentation.\n* Pyonephrosis requiring a non-randomized drainage decision.\n* Anatomical abnormalities affecting endoscopic access, such as horseshoe kidney, pelvic kidney, ureterocele, or ureteral stricture.\n* Previous ipsilateral ureteral reconstructive surgery.\n* Uncorrected coagulopathy.\n* Pregnancy.\n* Genitourinary malignancy.\n* Inability to complete follow-up.",{"count":564,"type":22},90,[25],"Calculous anuria caused by obstructing upper ureteral stones in a solitary functioning kidney is a urological emergency requiring urgent decompression. Both retrograde JJ ureteral stenting and percutaneous nephrostomy are commonly used emergency drainage methods. However, limited evidence is available regarding whether the initial drainage method affects subsequent definitive flexible ureteroscopy\u002Fretrograde intrarenal surgery outcomes.\n\nThis multicenter prospective randomized controlled trial will compare emergency JJ ureteral stent drainage versus percutaneous nephrostomy drainage in adult patients presenting with calculous anuria due to a single upper ureteral stone in a solitary functioning kidney. After renal functional improvement, clinical stabilization, and appropriate urine culture management, all participants will undergo standardized definitive flexible ureteroscopy\u002Fretrograde intrarenal surgery. The study will assess renal functional recovery, first-session surgical success, stone-free rate, operative parameters, complications, and microbiological outcomes.",[568,569,570,571],"Calculous Anuria","Upper Ureteral Stone","Obstructive Uropathy","Acute Kidney Injury",[573,574,575],"Percutaneous nephrostomy","Double-J ureteral stent","Retrograde intrarenal surgery","2026-05-30",{"date":578,"type":33},"2026-06-04",{"date":580,"type":33},"2026-05-06",{"date":582,"type":22},"2027-04",{"name":39,"class":40},3,""]